LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces its unaudited half-year report for the six months ended 30 June 2024. Strong progress with our LungLB® product Continued operational delivery : Financial Highlights: Commenting Paul Pagano, Chief Executive […]
LungLife AI, Inc. (the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, is pleased to note the publication of the finalized Local Coverage Determination (LCD) titled “Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy” (L39654), issued by the Medicare Administrative Contractor (MAC) Noridian Healthcare […]
LungLife AI licensure/accreditation information posted here.